Aurobindo Pharma`s Unit III undergoes USFDA audit

Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) inspected Company`s Unit III, a Formulation manufacturing facility situated at Bachupally Village, Medchal Malkajgiri District, Telangana, from 14 July to 21 July 2023.

At the end of the inspection, the company has been issued a `Form 483` with 3 observations. The observations are procedural in nature. `We will respond to the US FDA within the stipulated timelines and work closely with US FDA to close the observations at the earliest`, the company said.

Powered by Capital Market - Live News